5 Key Takeaways
-
1
Current clinical trials for noninfectious uveitis are exploring systemic and local treatments, including TYK2/JAK1 modulators and IL-6 inhibitors.
-
2
Brepocitinib, a TYK2/JAK1 inhibitor, is undergoing a phase 3 trial to evaluate its efficacy in reducing inflammation in noninfectious uveitis.
-
3
Vamikibart, an IL-6 inhibitor, is being tested for uveitic macular edema and has shown a favorable safety profile in early trials.
-
4
KSI-101 combines IL-6 inhibition with a VEGF trap and is set to initiate pivotal studies in 2025, aiming for enhanced treatment durability.
-
5
Dazdotuftide (TRS01) is a topical treatment showing promise in reducing inflammation for anterior uveitis without increasing intraocular pressure.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.